scholarly journals Processing and storage of blood components during the COVID-19 pandemic

2020 ◽  
Vol 1 (3) ◽  
pp. 114-118
Author(s):  
Ana Antić ◽  
Sanja Živković-Đorđević ◽  
Marija Jelić ◽  
Miodrag Vučić ◽  
Nebojša Vacić ◽  
...  
Keyword(s):  
Shelf Life ◽  
Blood Donors ◽  
National Level ◽  
Blood Component ◽  
Blood Collection ◽  
Routine Practice ◽  
Blood Components ◽  
Pathogen Inactivation ◽  
Blood Processing ◽  
Number Of Patients

The spread of the COVID-19 virus has a strong influence on blood collection, maintaining a stable supply of all blood components and the safety of the transfusion itself. SARS-CoV-2 has a long incubation period (1-14 days, on average 5-6 days, longest reported 24 days) and causes asymptomatic infection in a large number of patients, which is a great challenge in a recruitment of blood donors and achieving a safe transfusion. Precise recommendations and precautions have been adopted regarding the criteria for temporary refusal of blood donors during the COVID-19 pandemic, organization of mobile teams and collection sites, disposal of medical waste, examination of potential donors and mandatory body temperature measurement. Although transmission of COVID-19 via blood and blood components has not been demonstrated, some countries have also introduced mandatory NAT testing for SARS-CoV-2 as a part of blood screening testing. Also, proactive measures have been taken, such as temporary storage of blood in quarantine for 14 days after collection, while special attention is paid to efficient management of blood component stocks and development of a collection plan, in order to avoid shortage of certain blood components or their expiration. The first step in this regard is to revise the measures which have the aim for improving the usability of blood components, ie reducing waste of stocks, which primarily refers to the temporary extension of the shelf life of blood components. Extending the shelf life of erythrocytes (longer than 35 to 49 days, which is defined at the national level) should be considered as early as possible, because once a shortage of erythrocytes occurs, they will be issued long before the expiration date. Previous studies have not shown significant side effects of erythrocyte transfusion with extended shelf life, so it is possible to consider the flexibility of blood processing and erythrocyte storage conditions with mandatory internal process validation and component quality control. The shelf life of platelet concentrate should be extended from 5 days to 7 or even 8 days, with mandatory bacteriological testing or pathogen inactivation. Another option to increase the platelet supply for prophylactic purposes is to reduce the platelet dose by dividing the existing components. Frozen fresh plasma has the longest shelf life (up to 3 years), so maintaining stable reserves is much safer than for cellular components. Liquid plasma (never previously frozen) has a shelf life of 7-40 days, and can be used in conditions of reduced freezer capacity, shortage of staff working on blood processing or for the production of convalescent plasma. Pathogen inactivation of plasma and platelets allows 3-6 log reduction of SARS-CoV-2 and MERS-CoV. The decision to introduce some of the methods of pathogen inactivation should be made taking into account the costs and resources required for implementation. For countries that do not have pathogenic inactivation already in routine practice, its rapid introduction is a big task. For now, the risk of SARS-CoV-2 transmission through the blood appears to be very low, although our understanding of the virus and behavior during a pandemic will improve over time. In this regard, pathogen inactivation of convalescent plasma should also be considered.

scholarly journals New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

2020 ◽  
Vol 4 (2) ◽  
pp. 53-66
Author(s):  
Luca Galli ◽  
Fabrizio Bruschi
Keyword(s):  
Blood Donors ◽  
Parasitic Diseases ◽  
Infectious Agents ◽  
Blood Components ◽  
Pathogen Inactivation ◽  
Blood Safety ◽  
New Agents ◽  
Set Up ◽  
The Impact ◽  
New Strategies

AbstractAround 70 infectious agents are possible threats for blood safety.The risk for blood recipients is increasing because of new emergent agents like West Nile, Zika and Chikungunya viruses, or parasites such as Plasmodium and Trypanosoma cruzi in non-endemic regions, for instance.Screening programmes of the donors are more and more implemented in several Countries, but these cannot prevent completely infections, especially when they are caused by new agents.Pathogen inactivation (PI) methods might overcome the limits of the screening and different technologies have been set up in the last years.This review aims to describe the most widely used methods focusing on their efficacy as well as on the preservation integrity of blood components.

Thrombin generation before and after multicomponent blood collection

2008 ◽  
Vol 28 (S 01) ◽  
pp. S73-S76
Author(s):  
C. Cimenti ◽  
S. Sipurzynski ◽  
S. Gallistl ◽  
A. Rosenkranz ◽  
M. Hiden ◽  
...  
Keyword(s):  
Thrombin Generation ◽  
Blood Donors ◽  
Blood Collection ◽  
Blood Components ◽  
Donor Blood ◽  
Donor Safety ◽  
Function Test ◽  
Before And After

SummaryIThe development of apheresis technology has increased efficiency in donor blood use by collecting specific blood components in several combinations. The question of donor safety raised by the contact of donor blood with foreign, only in part biocompatible surfaces remains. The aim of this study was to estimate the effect of multicomponent blood collection on thrombin generation performing an overall function test of coagulation. Donors, methods: 26 blood donors were included. Per apheresis two units of platelets and one unit of RBCs were collected by two cell separators (Amicus® and Trima Accel®). Each donor underwent the procedure on both apheresis systems. Samples were collected before, immediately after, and 48 hours after apheresis. Thrombin generation was measured by means of calibrated automated thrombography (CAT). Results: CATdata changed only slightly and no significant changes were seen before, immediately after, and 48 hours after apheresis. The parameters did not differ significantly between the two different apheresis devices. Conclusion: No change in parameters of continuous thrombin generation occurred, suggesting that apheresis did not lead to severe alterations in the haemostatic system.

The physiology of blood in anaesthetic practice

2017 ◽  
Author(s):  
Hanane El Kenz ◽  
Philippe Van der Linden
Keyword(s):  
Blood Transfusion ◽  
Whole Blood ◽  
Fresh Frozen Plasma ◽  
Blood Component ◽  
Blood Components ◽  
Pathogen Inactivation ◽  
Septic Complications ◽  
Packed Red Blood Cells ◽  
Blood Component Therapy ◽  
Fresh Frozen

Following the discovery of the ABO blood groups by Landsteiner in 1901, Albert Hustin described the first transfusion of a whole blood unit in 1914. The modern transfusion era really begins in 1916 with the discovery of sodium citrate as an anticoagulant by the same physician, allowing blood conservation in dedicated packs. Since that time, many advances have been made especially over the past two decades in the storage, the conservation, and the laboratory testing of blood components and in transfusion medicine practice. Transfusion of whole blood has been replaced by blood component therapy, which consists of the administration of packed red blood cells, fresh frozen plasma, or platelets. Although blood transfusion is safer than ever, the risk of complications will never reach zero. The risk of infectious transfusion-transmitted diseases has been markedly reduced by the implementation of extensive infectious disease testing, donor selection, and pathogen-inactivation procedures. In countries with a high human development index, the leading causes of allogeneic blood transfusion-related deaths actually resulted from immunological and septic complications. The first section of this chapter describes the structure, function, and immunological aspects of the different blood components that are routinely transfused today. The second section details the composition of the different blood components, their indications, the pre-transfusion compatibility tests, and the main adverse effects associated with their transfusion.

scholarly journals Rational Clinical Use of Blood and Blood products – A summary

2017 ◽  
Vol 7 (1) ◽  
pp. 1111-1117 ◽  
Author(s):  
D Ghartimagar
Keyword(s):  
Blood Component ◽  
Physiological Status ◽  
Blood Collection ◽  
Main Role ◽  
Blood Components ◽  
Blood Products ◽  
Right Reason ◽  
Compatible Blood ◽  
The Right

Blood transfusion is an essential therapeutic intervention. The main role of the blood centre is to provide safe and timely blood and blood component(s) to the patients that will improve the physiological status of the patient. Various blood components can be harvested from a single donation of whole blood. The blood centre ensures that there is an adequate inventory of all blood types and blood components to meet the needs of the patients. The blood centre does donor selection, blood collection, component preparation, screening for transfusion – transmitted infections and blood processing. Serologically compatible blood and components are provided to the patients after meticulous pre-transfusion testing as per the standard protocol. Rational use of blood and blood products means right product is used with the right dose on right time for the right reason.

scholarly journals Physiological Parameters to Identify Suitable Blood Donor Cows for Preparation of Platelet Rich Plasma

Animals ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 2296
Author(s):  
Anna Lange-Consiglio ◽  
Rosangela Garlappi ◽  
Chiara Spelta ◽  
Antonella Idda ◽  
Stefano Comazzi ◽  
...  
Keyword(s):  
Blood Donor ◽  
Blood Donors ◽  
Platelet Rich Plasma ◽  
Bovine Mastitis ◽  
Field Conditions ◽  
Blood Collection ◽  
Experimental Conditions ◽  
Acute Mastitis ◽  
Donor Cows ◽  
The Ideal

Platelet rich plasma (PRP) has been shown to be beneficial in the treatment of bovine mastitis, with an action comparable to that of antibiotics. Autologous treatment is feasible in experimental conditions but is difficult to apply in field conditions, particularly in acute mastitis. The ideal scenario would be to have heterologous PRP stored on every farm so that it is readily available when needed. In this paper, we analysed data collected during bovine mastitis treatment with heterologous PRP produced by casual donor cows on several farms. We tried to identify parameters which might be useful to identify the most suitable cows to be used as blood donors, to obtain the highest yield of PRP. Variables considered for each animal were the age, the parity, the date of the last parturition, the season of blood collection, the site of blood collection (jugular or mammary vein) and the reproductive status e.g., pregnant or not pregnant. There were statistically significant differences for all the variables considered from the 135 blood cows, except for the blood collection season. The highest yield of PRP was associated with nonpregnancy blood collection within three months of parturition, parity 3 or 4, and blood collection from the mammary vein.

Sonographic Evaluation of Hidradenitis Suppurativa with Smartphone-Linked Portable Ultrasound

Dermatology ◽  
2021 ◽  
pp. 1-5
Author(s):  
Maximillian A. Weigelt ◽  
Yuval Hilerowicz ◽  
Jeffrey A. Leichter ◽  
Hadar Lev-Tov
Keyword(s):  
Hidradenitis Suppurativa ◽  
Wound Care ◽  
University Hospital ◽  
Clinical Staging ◽  
Routine Practice ◽  
Portable Ultrasound ◽  
Number Of Patients ◽  
Staging Systems ◽  
Conventional Ultrasound ◽  
Potential Benefits

Background: Clinical staging systems for hidradenitis suppurativa (HS) have poor interrater reliability and may underestimate disease activity. Sonographic staging systems may overcome these challenges, but conventional ultrasound (US) machines are expensive and bulky. Portable (p)US may facilitate the integration of sonography into routine practice. Objectives: To assess the ability of a novel smartphone-linked pUS device to identify key sonographic lesions of HS. Methods: The charts of 16 patients with HS who were assessed with pUS at the outpatient Dermatology and Wound Care Clinics of a university hospital center were retrospectively reviewed. Clinical and sonographic images of the affected areas were examined. The main outcome measures were the number of patients with identifiable sonographic lesions and the number of patients with subclinical lesions detected by pUS. Results: All 3 key sonographic lesions of HS were identifiable with pUS. Sonographic lesions were identified in 10 patients (62.5%). Subclinical lesions were identified in 2 patients (12.5%); in both cases, this affected management decisions. Conclusions: We demonstrate the ability of pUS to identify the key sonographic lesions of HS. pUS is a simple and affordable way to integrate HSUS into clinical and research settings, with clear potential benefits to patients.

scholarly journals Perioperative hemodynamic optimization: from guidelines to implementation—an experts’ opinion paper

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jean-Luc Fellahi ◽  
Emmanuel Futier ◽  
Camille Vaisse ◽  
Olivier Collange ◽  
Olivier Huet ◽  
...  
Keyword(s):  
High Risk ◽  
Fluid Therapy ◽  
Postoperative Morbidity ◽  
Large Body ◽  
Surgical Patients ◽  
Cardiac Output Monitoring ◽  
Routine Practice ◽  
Daily Routine ◽  
Hemodynamic Optimization ◽  
Number Of Patients

AbstractDespite a large body of evidence, the implementation of guidelines on hemodynamic optimization and goal-directed therapy remains limited in daily routine practice. To facilitate/accelerate this implementation, a panel of experts in the field proposes an approach based on six relevant questions/answers that are frequently mentioned by clinicians, using a critical appraisal of the literature and a modified Delphi process. The mean arterial pressure is a major determinant of organ perfusion, so that the authors unanimously recommend not to tolerate absolute values below 65 mmHg during surgery to reduce the risk of postoperative organ dysfunction. Despite well-identified limitations, the authors unanimously propose the use of dynamic indices to rationalize fluid therapy in a large number of patients undergoing non-cardiac surgery, pending the implementation of a “validity criteria checklist” before applying volume expansion. The authors recommend with a good agreement mini- or non-invasive stroke volume/cardiac output monitoring in moderate to high-risk surgical patients to optimize fluid therapy on an individual basis and avoid volume overload. The authors propose to use fluids and vasoconstrictors in combination to achieve optimal blood flow and maintain perfusion pressure above the thresholds considered at risk. Although purchase of disposable sensors and stand-alone monitors will result in additional costs, the authors unanimously acknowledge that there are data strongly suggesting this may be counterbalanced by a sustained reduction in postoperative morbidity and hospital lengths of stay. Beside existing guidelines, knowledge and explicit clinical reasoning tools followed by decision algorithms are mandatory to implement individualized hemodynamic optimization strategies and reduce postoperative morbidity and duration of hospital stay in high-risk surgical patients.

Factors Affecting Transfusion of Fresh Frozen Plasma, Platelets, and Red Blood Cells During Elective Coronary Artery Bypass Graft Surgery

2003 ◽  
Vol 127 (4) ◽  
pp. 415-423
Author(s):  
Randal Covin ◽  
Maureen O'Brien ◽  
Gary Grunwald ◽  
Bradley Brimhall ◽  
Gulshan Sethi ◽  
...  
Keyword(s):  
Blood Cells ◽  
Prediction Models ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Fresh Frozen Plasma ◽  
Blood Component ◽  
Artery Bypass Graft ◽  
Blood Components ◽  
Fresh Frozen ◽  
Frozen Plasma

Abstract Context.—The ability to predict the use of blood components during surgery will improve the blood bank's ability to provide efficient service. Objective.—Develop prediction models using preoperative risk factors to assess blood component usage during elective coronary artery bypass graft surgery (CABG). Design.—Eighty-three preoperative, multidimensional risk variables were evaluated for patients undergoing elective CABG-only surgery. Main Outcome Measures.—The study endpoints included transfusion of fresh frozen plasma (FFP), platelets, and red blood cells (RBC). Multivariate logistic regression models were built to assess the predictors related to each of these endpoints. Setting.—Department of Veterans Affairs (VA) health care system. Patients.—Records for 3034 patients undergoing elective CABG-only procedures; 1033 patients received a blood component transfusion during CABG. Results.—Previous heart surgery and decreased ejection fraction were significant predictors of transfusion for all blood components. Platelet count was predictive of platelet transfusion and FFP utilization. Baseline hemoglobin was a predictive factor for more than 2 units of RBC. Some significant hospital variation was noted beyond that predicted by patient risk factors alone. Conclusions.—Prediction models based on preoperative variables may facilitate blood component management for patients undergoing elective CABG. Algorithms are available to predict transfusion resources to assist blood banks in improving responsiveness to clinical needs. Predictors for use of each blood component may be identified prior to elective CABG for VA patients.

Sign in / Sign up

Export Citation Format

Share Document